ATLASDamora Therapeutics (DMRA) earnings date: Nov 5, 2026
Damora Therapeutics (DMRA) reports earnings for the quarter ended Sep 30, 2026 on Thu, Nov 5, 2026, after the close. Analysts expect EPS of -$0.52.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on DMRA
| Last price | $21.49 (-2.4%) |
|---|---|
| Normal 1-day range (±1σ) | ±3.9% |
| Earnings beat history | Beat the EPS estimate in 3 of the last 5 reports |
These figures come from the same calibrated model and valuation as the Damora Therapeutics stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Damora Therapeutics reports on Nov 5, 2026. One email the day before, with ATLAS’s read on Damora Therapeutics. You can switch it off at any time.
Alert me before DMRA reportsFree to start. Creating an account takes under a minute.
DMRA earnings at a glance
| Next report (confirmed) | Thu, Nov 5, 2026 |
|---|---|
| Time | After the close |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | -$0.52 |
| Last report | Aug 10, 2026 · Miss |
| Beat rate (last 5 reports) | 3 of 5 (60%) |
| Average EPS surprise | -10.6% |
| Average move around a report | ±4.0% (last 5) |
| Sector | Healthcare · Biotechnology |
Damora Therapeutics earnings history: last 5 reports
Damora Therapeutics last reported on Aug 10, 2026: EPS of -$0.39 against an estimate of -$0.37 (-5.4% surprise), a miss.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Aug 10, 2026 | -$0.37 | -$0.39 | -5.4% | Miss | +1.5% |
| Jul 10, 2026 | $1.49 | $1.56 | +4.7% | Beat | -9.0% |
| Mar 19, 2025 | -$2.82 | -$5.00 | -77.3% | Miss | -3.5% |
| Nov 1, 2024 | -$3.70 | -$3.39 | +8.4% | Beat | -1.8% |
| Aug 12, 2024 | -$6.00 | -$5.00 | +16.7% | Beat | +4.0% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for DMRA
See the fair value, the probability range and the earnings history of Damora Therapeutics on its ATLAS page.
Damora Therapeutics (DMRA) stock analysisPlans from €3.99 a month.
Damora Therapeutics earnings: frequently asked questions
When does Damora Therapeutics (DMRA) report earnings?
Damora Therapeutics is scheduled to report on Thursday, November 5, 2026, after the close. ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for DMRA?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is -$0.52 per share (USD). Estimates can change before the report.
How often does DMRA beat earnings estimates?
Of its last 5 reports with a recorded result, Damora Therapeutics beat the EPS estimate 3 times; the average surprise was -10.6%. Past results do not predict the next one.
How much does DMRA move around earnings?
Over its last 5 reports the stock moved an average of 4.0% (absolute, from the close before the report day to the close after it), and finished higher 2 of 5 times.
Did Damora Therapeutics beat earnings estimates last quarter?
Damora Therapeutics last reported on Aug 10, 2026: EPS of -$0.39 against an estimate of -$0.37 (-5.4% surprise), a miss.
How much does DMRA usually move in a day?
On a normal trading day the ATLAS model puts DMRA’s one-day range at about ±3.9%, with a 49% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Thu, Nov 5, 2026
Educational information, not investment advice. Disclaimer